High titers of neutralizing antibodies in human immunodeficiency virus type 1 (HIV-1) infection are directed primarily against the third hypervariable domain (V3) of the virion envelope glycoprotein gpl20. This region has been designated the principal neutralizing domain of HIV-1. Because the frequency and significance of autologous V3 antibodies in natural infection are not fully clarified, we have cloned, sequenced, and expressed the V3 domain from virus of HIV-1-infected patients to test the autologous and heterologous V3 antibody response. The resulting recombinant Escherichia coli V3 fusion proteins reacted strongly with both autologous and heterologous patient antibodies in Western blots. Thirty-one different V3 fragments were cloned from 24 hemophiliac patients with different immunological and clinical statuses. Antibody reactivity against the autologous V3 fusion proteins was detected in all serum samples except one; moreover, all serum samples contained antibody reactivity against a vast majority of heterologous fusion proteins despite significant amino acid variability in V3. The results suggest that V3 antibodies are highly prevalent; further, we find no association between the stage of the HIV-1 infection and the presence of V3 antibodies.
The third hypervariable domain of gp120 (V3) (26) elicits potent type-specific neutralizing antibodies in immunized and experimentally infected animals (20, 30, 32) . V3 antibodies block both cell-free infection and the gpl20-CD4-mediated syncytium formation in vitro (25, 34) . V3 antibodies do not interfere with the binding of gp120 to CD4, suggesting that the antibodies block a postbinding event required for infectivity (39) . The V3 domain generates a loop structure in gpl20 facilitated by an intrachain disulfide bond between the terminal cysteine residues (24) . Neutralizing V3 antibodies have been shown to block a site-specific proteinase cleavage of the V3 loop in CD4-bound recombinant gpl20 (7) . Consequently, such antibodies have been proposed to inhibit a similar essential processing of gp120 by a host cell proteinase during the initial steps of infection (7) .
The immunoglobulin G fraction of antibodies from human immunodeficiency virus (HIV)-infected chimpanzees can neutralize viral infectivity, since challenge of naive animals with virus treated with these antibodies does not lead to infection (9) . Further, protective vaccination of chimpanzees with recombinant gpl20 elicits high titers of V3 antibodies, whereas only low titers are found by parallel nonprotective vaccination with recombinant gpl60 (2) . Similar protection by vaccination has also been achieved by vaccination of chimpanzees with a mixture of inactivated virus, gpl60, and V3 peptides (13) . Finally, passive immunization of chimpanzees with a V3 antibody protects against infection following challenge with virus (10) . Thus, these data indicate that V3 antibodies may confer part of the protection against challenge with HIV in chimpanzees. Likewise, since the majority of the HIVMN-neutralizing activity in serum can be absorbed with an MN homologous V3 peptide (31) and since a neutralizing human monoclonal antibody defining an epitope in V3 has been generated from an HIV-infected individual (37) , part of the neutralizing response discovered in natural infection probably also consists of V3 antibodies. However, the role of these antibodies during primary infection and their role in controlling the progression of an established HIV infection are not well characterized.
We have addressed the question of V3 antibody frequency and significance in natural infection. Using nested-primer polymerase chain reaction (PCR), we have sequenced, cloned, and expressed V3 sequences in order to determine the V3 variability and frequency of autologous antibody reactivity in HIV-infected individuals with different immunological and clinical statuses. This approach revealed that autologous antibodies against V3 were highly prevalent.
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MATERIALS AND METHODS
Oligonucleotide primers. Viral DNA was cloned by nestedprimer PCR amplification with the oligonucleotide outer primer set L5' (5'AGC ACA GTA CAA TGT ACA CAT GGA AT 3') and L3' (5'AAA TTC CCC TCC ACA ATT AAA ACT GTG 3') defining a DNA fragment corresponding to amino acids 249 to 389 of gpl20. Amino acid numbering was as described elsewhere (33) . The (22) . The results were arbitrarily scored according to the following four categories on the basis of visual evaluation of the staining intensity: -, no reactivity; 1, weak reactivity; 2, moderate reactivity; 3, good reactivity (Fig. 1) .
Amino acid sequence accession number. The amino acid sequences listed in Table 2 are available under EMBL data library accession numbers P80112 through P80142 and P04578.
RESULTS
Culture of virus and amplification of the corresponding V3 DNA. To ensure that V3 sequences were amplified from replication-competent HIV, virus was propagated from patient PBMC by coculture with PHA-stimulated normal donor PBMC. PBMC from hemophiliac patients infected with HIV from different factor VIII preparations were used for virus isolation to ensure diversity of the viral strains. To overcome the potential problems of primer mismatch that may arise when PCR is applied for amplification of hypervariable nucleotide sequences, viral DNA was amplified by nestedprimer PCR. Cell cultures were screened for HIV infection with an outer primer pair which was complementary to conserved env regions and produced a DNA fragment corresponding to amino acids 249 to 389 of gpl20. Subsequently, the viral DNA was sequenced, and inner oligonucleotide primers matching the individual DNA fragments perfectly were generated for amplification and cloning of the DNA corresponding to V3. The efficiency of the screening with the outer primer pair was initially monitored by double screening of 10 cultures by reverse transcriptase assay and PCR. The results of the two screening methods were identical (data not shown), since a DNA fragment containing V3 could be amplified from all reverse transcriptase-positive cultures with the primers L5' and L3'. Moreover, the amplification strategy excluded the risk of primer-induced mutagenesis of V3 by the use of perfect matching primers for generation of the secondary PCR product.
Virus was isolated from 24 patient samples, and viral DNA was subsequently amplified. Viral DNA was amplified from 24 cultures at day 9 after infection, and the remaining 7 cultures were further maintained until day 35; however, no viral DNA could be amplified from these cultures despite attempts at several time points. In addition, viral DNA was amplified from a PBMC culture infected with the reference isolate human T-cell leukemia virus IIIB (HTLV-IIIB). Direct sequencing of the amplified DNA fragments (each containing the entire nucleotide sequence of V3) showed that all sequences were unique. The products of at least three individual PCR amplifications from each culture were directly sequenced and compared to detect any possible Taq polymerase-induced point mutations; however, none was observed.
None of the 25 DNA fragments contained stop codons or frameshift mutations in the region corresponding to V3, but the DNA amplified from eight patients contained a mixture of two nucleotides at various positions on the sequence ladder (data not shown). Moreover, the sequence amplified from patient no. 291 and the HTLV-IIIB-infected cell sequence contained insertions of 12 and 3 nucleotides, respectively, compared with the remaining sequences (data not shown). The sequence of the V3 DNA amplified from HTLV-IIIB-infected cells was identical to that of the molecular clone HXB2.
Cloning and expression of amplified DNA fragments. The primary amplification product corresponding to amino acids 249 to 389 was used as the template for a second amplification with oligonucleotide primers, producing a DNA fragment corresponding to amino acids 298 to 345. These secondary PCR products were cloned into the prokaryotic expression vector pUEX, and the sequences of the constructions were verified by sequencing. Each of the cloned V3 sequences (Table 2) corresponded perfectly with the sequences obtained by direct sequencing of the primary PCR products.
From five of the primary amplification products derived from patients no. 288, 296, 303, 306, and 314, which contained mixed genotype in some nucleotide positions, more than one clone was selected. The specific sequences of these additional clones corresponded with the locations of the mixed nucleotides in the primary amplification products, indicating that the mixed nucleotides represented true heterogeneity in the viral strain. Thus, from the 25 primary amplification products, 32 different DNA fragments corresponding to amino acids 298 to 345 of gpl20 were cloned into pUEX, including the HXB2 V3 fragment (Table 2) . Sequence analysis showed that the variability within the V3 domain was confined to certain clusters of the sequence and that apart from the terminal cysteine residues, the central Initially, all recombinant fusion proteins were tested with a pool of HIV antibody-negative sera (n = 50) without detection of reactivity (data not shown). Conversely, a pool of HIV antibody-positive sera (n = 50) reacted with the recombinant fusion proteins but did not react with the parental Cro-fi-galactosidase fusion protein produced by induction of the native pUEX vector (data not shown).
Equal amounts of recombinant bacterial fusion protein were tested with the patient sera. Twenty-four serum samples corresponding to the PCR-positive patient samples were tested for reactivity with the 31 autologous recombinant fusion proteins (Tables 2 and 3 ). Further, serum samples from all 31 patients (the 24 PCR-positive patients and the 7 PCR-negative patients from whom viral DNA could not be amplified) were cross-tested for antibody reactivity against all 32 heterologous recombinant fusion proteins (Table 4) .
All sera tested in this study contained autologous antibody response against the corresponding antigen, with the exception of serum sample no. 291. A similar lack of reactivity with protein no. 291 was also found for four consecutive autologous serum samples dating 3 years back and for a serum pool derived from 50 HIV-positive individuals (data not shown). However, serum sample no. 291 readily reacted with the majority of the heterologous V3 fusion proteins (Table 4) , and V3 antibodies were thus found in all of the serum samples, independently of the immunological and clinical statuses of each patient (Table 1) . Most proteins containing the central sequence PGRAFYTT or PGRAFY AT reacted with heterologous serum samples from patients with an identical sequence. In contrast, the HXB2 V3 sequence reacted moderately with only one serum sample, whereas five samples reacted weakly. Moreover, protein no. 304 containing a proline residue adjacent to the central sequence (Table 2) reacted with a small number of heterologous serum samples. Finally, proteins no. 288-2, 305, and 317, each containing an R-G substitution in the central sequence, reacted with a small number of heterologous serum samples, whereas substitutions in other positions of this sequence (proteins no. 301, 306-5, 306-7, 314-B, and 314-C) affected the reactivity with heterologous sera to a lesser extent.
Accordingly, amino acid insertions and some substitutions within the central V3 sequence PGRAFYTT appeared to affect the reactivities of heterologous sera against the recombinant proteins. Thus, proteins no. 288-2, 291, 304, 305, and 317 and the HXB2 V3 protein reacted with a smaller number Group ld 288-1  2  2  7  18  3  288-3  3  1  3  6  20  288-4  3  0  3  7  20  289  3  1  4  4  21  290  3  0  2  3  25  292  2  0  13  14  3 -B  3  0  7  14  9  314-C  3  0  6  15  9  315  3  0  1  1  28  316  3  0  0  2  28  319  3  0  1  5  24   Group 2  288-2   -18  8  4  0  305  3  18  7  3  1  317  1  7  8  11  4 Group 3 Table 2 . b Graduated reactivity of patient sera with the autologous recombinant fusion proteins: 3, good; 2, moderate; 1, weak; -, no reactivity; ND, no data (Fig. 1). c Number of graduated reactivities of heterologous patient sera with the individual recombinant fusion proteins. See footnote b for description of scoring code.
d Groupings based on related serological reactivities.
of serum samples than did the remaining proteins (Tables 2  and 3 ).
DISCUSSION
Despite the extensive humoral and cellular immune response following challenge with HIV, the infection persists and appears to evade the immune system. The virus envelope proteins are major targets for antibody responses, and several B-cell epitopes have been mapped elsewhere in detail (5, 14-16, 21, 29, 30, 37, 40) , but only epitopes in V3 appear to elicit high titers of in vitro neutralizing antibodies (3, 16, 37) . (20) indicate that the amino acid variability found in V3 (27) may create an indefinite number of serotypes. However, our study tends to suggest that the variability of the V3 antigenic determinants in field isolates is less extensive than the variability among molecular clones of HIV from different laboratories (27) .
By cross-testing of sera and recombinant fusion proteins, the amino acids of particular importance for antibody reactivity appeared to reside within the central sequence PGRAFYTT. This sequence has previously been shown to constitute an epitope defined by a human monoclonal antibody (37) . Fusion proteins containing a central PGRAFYTT or PGRAFYAT sequence reacted with the majority of heterologous sera, whereas heterologous reactivity against proteins no. 288-2 (GIHMGPGQAFXTr), 305 (SIHLGPG iAFYAT), and 317 (SIHIGPGiAFRTT) ( Thus, amino acid substitutions within the PGRAFYTT sequence in positions 1, 2, 3, and 4 and to some extent position 5 appeared to have the most prominent effect on heterologous reactivity, whereas substitutions in positions 6, 7, and 8 had less effect. In addition, the presence of a proline residue adjacent to the central sequence as found in protein no. 304 had a marked effect on heterologous antibody reactivity, as previously described (42) . Accordingly, lessfrequent antibody reactivity was detected in heterologous sera against fusion proteins containing insertions and/or an aberrant amino acid composition in the central part of the V3 sequence.
Since parts of V3 are conserved and since the major antigenic determinants appear to reside only in the center of V3, the number of serotypes appears to be small. However, the insertions in protein no. 291 infrequently (23) and are not found in experimentally infected chimpanzees (28) .
During primary infection of humans and chimpanzees, the neutralizing effect of antibodies against concurrently isolated virus declines (1, 28) . Analysis of V3 from chimpanzees reveals that mutations in V3 appear subsequent to the onset of the stage of neutralization escape. Accordingly, neutralization-resistant viruses isolated early do not contain altered V3 sequences, whereas prechallenge vaccination with V3 peptides generates a rapid antigenic drift in V3 and accelerates neutralization escape (28) . These observations may explain our frequent detection of autologous V3 antibodies in all stages of the infection. Thus, despite a potent in vitro neutralizing effect, V3 antibodies may apparently mediate only an early and transient selective pressure on the virus in vivo (28) . Ultimately, this may be unable to prevent progression of the latent infection into significant immunodeficiency, although our present data cannot fully support this assumption since we address only the frequency of V3 antibody binding.
